Analysis in mutation profile of c-kit and platelet derived growth factor receptor A gene exon and clinicopathological characteristics in gastrointestinal stromal tumors

SHI Lei; CHEN Ping; WANG Hao; ZHAO Wei; FU Deyuan

doi:10.7619/jcmp.20211943

Journal of Clinical Medicine in Practice > 2021 > 25(13): 45-52. > DOI: 10.7619/jcmp.20211943

SHI Lei, CHEN Ping, WANG Hao, ZHAO Wei, FU Deyuan. Analysis in mutation profile of c-kit and platelet derived growth factor receptor A gene exon and clinicopathological characteristics in gastrointestinal stromal tumors[J]. Journal of Clinical Medicine in Practice, 2021, 25(13): 45-52. DOI: 10.7619/jcmp.20211943

Citation:

PDF (2456 KB)

Analysis in mutation profile of c-kit and platelet derived growth factor receptor A gene exon and clinicopathological characteristics in gastrointestinal stromal tumors

1.
Department of Gastrointestinal Surgery, Subei People's Hospital in Jiangsu Province, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, 225001
2.
Department of Thyroid and Breast Surgery, Subei People's Hospital in Jiangsu Province, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, 225001

More Information

Received Date: May 09, 2021
Available Online: July 05, 2021
Published Date: July 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To analyze the types and characteristics of c-kit and platelet derived growth factor receptor A (PDGFRA) gene mutations in gastrointestinal stromal tumors (GIST) and their relationships with clinicopathological characteristics of GIST.
Methods The clinicopathological data and tumor tissue specimens of 288 patients with GIST were collected, and the polymerase chain reaction amplification-direct sequencing method was used to detect the mutation status of c-kit (exons 9, 11, 13, 17) and PDGFRA gene (exons 12, 18), and the relationships between mutation types, sites and clinicopathological characteristics were analyzed.
Results Among the 288 GIST cases, 244 cases were primary mutations type (84.72%), 10 cases were secondary drug-resistant mutations type (3.47%), and 34 cases were wild-type (11.81%). Among the 244 patients with primary mutant GIST, there were 231 (94.67%) mutations in the c-kit gene, and the mutations in exons 9, 11, 13, and 17 were 25, 189, 7, and 10 cases, respectively. There were 13 cases with PDGFRA gene mutation, of which exon 12 and 18 mutations were 3 and 10 cases, respectively. Among 189 cases with c-kit gene exon 11 mutations, 111 cases (58.73%) were deletion mutations, 65 cases (34.39%) were point mutations, 3 cases were repeated mutations (1.59%), 4 cases were insertion mutations (2.12%), and 6 cases were mixed mutations (3.17%). The hot spot of exon 11 mutation was codons 557 to 560. The mutation site was related to the primary tumor site, tumor size and mitotic count (P < 0.05). The type of mutation was related to the patient's age, primary site of tumor, tumor size, mitotic count and modified National Institutes of Health (NIH) risk classification (P < 0.05). Logistic regression analysis showed that GIST patients aged more than 60 years old, with deletion mutations and c-kit exon 11 mutations had an increased risk of modified NIH risk classification by 2.060 (95%CI was 1.066 to 3.980), 3.264 (95%CI was 1.628 to 6.545) and 3.819 (95%CI was 1.585 to 9.205) times.
Conclusion The c-kit and PDGFRA genes in GIST have a high mutation rate and diverse mutation types or sites, which are closely related to the clinicopathology and prognosis of GIST patients, and can provide a reference for the whole-process management of GIST.
- gastrointestinal stromal tumor,
- c-kit,
- platelet derived growth factor receptor A,
- gene mutation

FullText(HTML)

References (20)

References

[1]	FLETCHER C D M, BRIDGE J A, HOGENDOORN P C W, et al. WHO classification of tumours of soft tissue and bone[M]. 4th Edition. Lyon: IARC Press, 2013: 164-167.
[2]	中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017年版)[J]. 肿瘤综合治疗电子杂志, 2018, 4(1): 31-43. doi: 10.3969/j.issn.2095-5324.2018.01.007
[3]	VON MEHREN M, JOENSUU H. Gastrointestinal stromal tumors[J]. J Clin Oncol, 2018, 36(2): 136-143. doi: 10.1200/JCO.2017.74.9705
[4]	WANG M, XU J, ZHAO W, et al. Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases[J]. Med Oncol, 2014, 31(1): 819. doi: 10.1007/s12032-013-0819-x
[5]	DOYLE L A, HORNICK J L. Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase[J]. Histopathology, 2014, 64(1): 53-67. doi: 10.1111/his.12302
[6]	HEINRICH M C, CORLESS C L, DUENSING A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors[J]. Science, 2003, 299(5607): 708-710. doi: 10.1126/science.1079666
[7]	SZUCS Z, THWAY K, FISHER C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications[J]. Future Oncol Lond Engl, 2017, 13(1): 93-107. doi: 10.2217/fon-2016-0192
[8]	李艳艳, 高静, 田野, 等. 827例胃肠间质瘤c-kit或PDGFRα基因突变谱解读及其与临床病理特征的关系[J]. 中华胃肠外科杂志, 2015, 18(4): 332-337. doi: 10.3760/cma.j.issn.1671-0274.2015.04.009
[9]	GOUNDER M M, MAKI R G. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor[J]. Cancer Chemother Pharmacol, 2011, 67(1): 25-43. http://europepmc.org/articles/PMC3275340/
[10]	HEINRICH M C, CORLESS C L, DEMETRI G D, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor[J]. J Clin Oncol, 2003, 21(23): 4342-4349. doi: 10.1200/JCO.2003.04.190
[11]	BARTHOLOMEW A J, DOHNALEK H, PRINS P A, et al. Underuse of exon mutational analysis for gastrointestinal stromal tumors[J]. J Surg Res, 2018, 231: 43-48. doi: 10.1016/j.jss.2018.05.014
[12]	陶凯雄, 张鹏. 胃肠间质瘤全程化管理[J]. 腹部外科, 2020, 33(1): 9-13. doi: 10.3969/j.issn.1003-5591.2020.01.003
[13]	ANDERSSON J, BÜMMING P, MEIS-KINDBLOM J M, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis[J]. Gastroenterology, 2006, 130(6): 1573-1581. doi: 10.1053/j.gastro.2006.01.043
[14]	孙祥飞, 高晓东, 袁伟, 等. 59例血小板源性生长因子受体α突变型胃肠间质瘤的临床病理特征和预后分析[J]. 中华胃肠外科杂志, 2020, 23(9): 880-887. doi: 10.3760/cma.j.cn.441530-20200320-00156
[15]	DUENSING S, DUENSING A. Targeted therapies of gastrointestinal stromal tumors (GIST): the next frontiers[J]. Biochem Pharmacol, 2010, 80(5): 575-583. doi: 10.1016/j.bcp.2010.04.006
[16]	孙祥飞, 高晓东, 沈坤堂. 胃肠间质瘤中伊马替尼继发性耐药机制的研究进展[J]. 中华胃肠外科杂志, 2019, 22(9): 886-890.
[17]	WARDELMANN E, MERKELBACH-BRUSE S, PAULS K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate[J]. Clin Cancer Res, 2006, 12(6): 1743-1749. doi: 10.1158/1078-0432.CCR-05-1211
[18]	GRAMZA A W, CORLESS C L, HEINRICH M C. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors[J]. Clin Cancer Res, 2009, 15(24): 7510-7518. doi: 10.1158/1078-0432.CCR-09-0190
[19]	KALFUSOVA A, LINKE Z, KALINOVA M, et al. Gastrointestinal stromal tumors-Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects[J]. Pathol Res Pract, 2019, 215(12): 152708. doi: 10.1016/j.prp.2019.152708
[20]	SERRANO C, MARIÑO-ENRÍQUEZ A, TAO D L, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours[J]. Br J Cancer, 2019, 120(6): 612-620. http://www.nature.com/articles/s41416-019-0389-6

[1]	LI Hongli, YAN Huili. Relationships of glucose metabolism with sex hormones and endometrial receptivity in patients with polycystic ovary syndrome at childbearing age[J]. Journal of Clinical Medicine in Practice, 2024, 28(10): 106-111. DOI: 10.7619/jcmp.20233856
[2]	LIU Xiaohong, LI Mei, WANG Fengyun, SI Yuchen, DU Xiaoli, SHI Liangliang, SHAO Haiou, CHEN Li, ZHANG Hongyan. Effect of modified Qiankun Yudan Decoction combined with leuprorelin acetate on serum carbohydrate antigen 125 and recurrence rate in patients with adenomyosis[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 133-137. DOI: 10.7619/jcmp.20231988
[3]	HUANG Dan, ZHU Yue, CUI Shuna. Value of inflammatory response indicators and tumor markers in predicting the prognosis of endometrial carcinoma patients undergoing surgery[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 26-31, 38. DOI: 10.7619/jcmp.20231381
[4]	WEI Weiwei, SHI Ruxia, MIN Yifei. Effect of laparoscopic surgery combined with gonadotropin-releasing hormone agonist in treatment of patients with adenomyoma of uterus[J]. Journal of Clinical Medicine in Practice, 2020, 24(23): 56-58. DOI: 10.7619/jcmp.202023018
[5]	XIAO Di, FU Yu, MENG Qi. Effects of levonorgestrel-releasing intrauterine system for dysmenorrhea patients with adenomyosis[J]. Journal of Clinical Medicine in Practice, 2020, 24(15): 51-54. DOI: 10.7619/jcmp.202015014
[6]	LIU Lingxiang, GAO Wen, LI Jun, HUANG Puwen, LIU Ping, SHU Yongqian. Analysis in clinical features and prognostic factors of 497 patients with endometrial cancer[J]. Journal of Clinical Medicine in Practice, 2016, (7): 86-89. DOI: 10.7619/jcmp.201607025
[7]	LI Yuping. The application of perioperative holistic nursing intervention in endometrial cancer patients[J]. Journal of Clinical Medicine in Practice, 2015, (10): 68-70,78. DOI: 10.7619/jcmp.201510021
[8]	LI Yanqi, CHEN Liping, WANG Zhixue. Expression of macrophage migration inhibitory factor in endometrial hyperplasia and type Ⅰ endometrial carcinoma and their correlation[J]. Journal of Clinical Medicine in Practice, 2013, (24): 72-74. DOI: 10.7619/jcmp.201324021
[9]	CHEN Jinghua, TANG Hui, YU Chuanhu, LI Wei. Research on recurrent situation and risk factors of endometrial cancer[J]. Journal of Clinical Medicine in Practice, 2013, (13): 145-147. DOI: 10.7619/jcmp.201313053
[10]	ZHU Suoyu, TAN Jie, YU Songmei. Clinical analysis of hysteroscopy in the treatment of 125 patient with endometrial polyps[J]. Journal of Clinical Medicine in Practice, 2012, (19): 79-80.

Cited By

Cited by

Periodical cited type(5)

1.	王烁. 胃十二指肠溃疡穿孔修补术护理对策及效果. 中国城乡企业卫生. 2025(03): 117-119 .
2.	翁昆仑，张鹏，张华甫. 经脐单孔腹腔镜胃十二指肠溃疡穿孔修补术治疗胃十二指肠溃疡穿孔患者的效果. 河南医学研究. 2023(21): 3964-3967 .
3.	蒲江玲. 早期营养支持护理联合健康教育在胃十二指肠溃疡穿孔患者中的应用效果. 中国当代医药. 2022(06): 189-192 .
4.	王佳佳. 急性胃十二指肠溃疡穿孔术后感染危险因素分析. 中国烧伤创疡杂志. 2022(02): 116-119 .
5.	刘俊. 分析整体护理运用于十二指肠溃疡患者的护理效果. 现代诊断与治疗. 2022(08): 1254-1256 .

Other cited types(0)

Get Citation

PDF

XML

Article views (2456) PDF downloads (240) Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Analysis in mutation profile of c-kit and platelet derived growth factor receptor A gene exon and clinicopathological characteristics in gastrointestinal stromal tumors